Retatrutide
Triple-Action Protocol
5mg × 10 vials — Weight Loss
10 vials — 12 months supply
The most anticipated next-generation weight loss compound. Phase 3 results generated massive excitement. The "24% weight loss" headline circulates widely.
What it does
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activation increases energy expenditure and hepatic fat oxidation — mechanisms absent from dual and single agonists.
This three-pathway approach represents the cutting edge of incretin-based research. Glucagon's role in increasing basal metabolic rate adds an energy expenditure component that pure appetite suppression compounds lack.
Dosage & Protocol
Subcutaneous injection, once weekly. Titration: 1mg (month 1), 2mg (month 2), 4mg (month 3), 8-12mg (month 4+). 10 vials provides approximately 12 months. Still in Phase 3 — no established clinical protocol yet.
What to expect
Who it's for
Read the full Retatrutide profile in the Peptide Bible
Dosing protocols, stacking guides, safety data, and research references.
The research
Safety notes
Pairs well with
Supports the enhanced fat oxidation from glucagon receptor activation
Gut support during aggressive weight loss
Complete Your Protocol
Frequently Asked Questions
Start My Triple-Action Protocol
5mg × 10 vials — 12 months supply — $280 — $0.77/day
Includes Peptide Bible, CoA certificate, and Telegram support